RBC Capital raised the firm’s price target on MannKind (MNKD) to $7 from $5 and keeps a Sector Perform rating on the shares. The company reported another strong quarter with total revenues up 37%, continued pull-through of Tyvaso DPI royalty and collaboration revenues, and appreciable Afrezza performance, supporting the topline, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.